Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Enanta Pharmaceuticals, Inc. - Common Stock
(NQ:
ENTA
)
7.700
+0.140 (+1.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Enanta Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Enanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
November 15, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor
November 12, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
October 19, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
October 06, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
October 05, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs
October 04, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021
October 01, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Investor Conferences in September
September 07, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
August 23, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer
August 16, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
August 05, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
August 05, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021
July 29, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
July 14, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™
June 23, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients
June 22, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Participate in Two Investor Conferences in June
June 10, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver
June 03, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
May 11, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
May 06, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor
May 06, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021
April 29, 2021
From
Enanta Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.